February 09, 2016

Bird Rock Bio Announces Corporate Name Change from RuiYi, Inc.

Change reflects evolution from discovery research to global clinical development company focused on developing innovative immuno-inflammatory regulators

Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, today announced its corporate name change from RuiYi, Inc. to Bird Rock Bio.
PDF Download

read more »

January 19, 2016

Aravis Biotech II: another exit

ACORDA ANNOUNCES A RECOMMENDED CASH TENDER OFFER FOR ALL SHARES, ADSs AND OTHER EQUITY INSTRUMENTS IN BIOTIE

Acorda Therapeutics, Inc. ("Acorda") and Biotie Therapies Corp. ("Biotie" or the "Company") have today entered into a combination agreement ("Combination Agreement") whereby Acorda, either directly or through a wholly-owned subsidiary (jointly the "Offeror"), will make a public tender offer in Finland and in the United States to purchase all of the issued and outstanding shares, American Depositary Shares ("ADSs"), stock options, share units and warrants in Biotie that are not owned by Biotie or any of its subsidiaries (the "Tender Offer").
PDF Download

read more »

January 19, 2016

Evolva clarifies key points in recent bank analyst note

Evolva (SIX: EVE) provides a clarification to Bank Vontobel’s analyst note of yesterday.

As previously reported, Evolva is in active discussions with Cargill regarding the optimal way to commercialise EverSweet™ and share the returns between Evolva and Cargill. These negotiations are being held in a positive and constructive manner.
PDF Download

read more »

January 11, 2016

Novimmune Completes CHF30 Million ($29.8 Million) Funding Round with Existing Shareholders

Broad Participation from Shareholder Base to Invest in Developing the Drug Pipeline, Including NI-0501 for Hemophagocytic Lymphohistiocytosis (HLH)

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, today announced it has completed a CHF30 million ($29.8 million) funding round.
PDF Download

read more »

January 07, 2016

Synaffix Appoints World Leading Experts to Scientific Advisory Board and Recruits Chairman to Board of Directors

Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced the appointment of a panel of industry experts to its inaugural scientific advisory board (SAB). Concurrent with the launch of the SAB, Synaffix has appointed Dr. Konstantinos Efthymiopoulos as the independent chairman of its Board of Directors.
PDF Download

read more »

January 05, 2016

ARAVIS terminates its energy activities

Aravis SA shut down its energy division as of 31 December 2015

Over the past six years, Aravis’ energy team has successfully invested in renewable energy assets across Europe. Investors in Aravis Energy I LP, a FINMA-regulated Swiss fund launched in 2009 and liquidated in 2015, received more than double of their commitments. The high return was attributable to the fund’s well differentiated build-and-sell strategy as well as the team’s ability to identify and exploit special situations, which enabled the fund to keep hold periods short and associated risks low. Besides Aravis Energy I LP, Aravis’ energy division has been accountable for a number of successful investments executed under advisory mandates.
PDF Download

read more »